Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Despite significant advances in early detection, surgery, radiotherapy, and systemic treatment of breast cancer, late relapse ...

Eli Lilly’s new weight-loss daily pill underperformed against competitors in weight... The Competition and Consumer ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

EUROPEAN shares logged their biggest daily rise in over two weeks on Thursday, boosted by financial stocks as investors ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...